What is Viatris's japan, australia and new zealand segment — net sales?

Viatris (VTRS) reported japan, australia and new zealand segment — net sales of $273.50M in Q1 2026.

How has Viatris's japan, australia and new zealand segment — net sales changed year-over-year?

Viatris's japan, australia and new zealand segment — net sales decreased by 1.3% year-over-year, from $277.10M to $273.50M.

What is the long-term trend for Viatris's japan, australia and new zealand segment — net sales?

Over 4 years (2021 to 2025), Viatris's japan, australia and new zealand segment — net sales has grown at a -12.3% compound annual growth rate (CAGR), from $2.03B to $1.20B.

Business Segments · Net Sales

Japan, Australia and New Zealand Segment — Net Sales

Viatris Japan, Australia and New Zealand Segment — Net Sales decreased by 10.8% to $273.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from $277.10M to $273.50M. Over 4 years (FY 2021 to FY 2025), Japan, Australia and New Zealand Segment — Net Sales shows a downward trend with a -12.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2018

Last reportedQ1 2026

Rolls up toTotal Revenue

How to read this metric

An increase suggests successful product adoption or market expansion, while a decrease may indicate competitive pressure or pricing challenges.

Detailed definition

This metric represents the total revenue generated from the sale of pharmaceutical products within the Japan, Australia,...

Peer comparison

Similar to regional net sales reported by other global pharmaceutical companies for their APAC or specific country clusters.

Metric ID: vtrs_segment_japan_australia_and_new_zealand_segment_net_sales

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$501.00M	$505.30M	$539.20M	$423.80M	$427.10M	$383.00M	$399.90M	$342.20M	$375.50M	$334.50M	$373.40M	$318.10M	$349.80M	$345.50M	$336.30M	$277.10M	$306.70M	$307.30M	$306.60M	$273.50M
QoQ Change	—	+0.9%	+6.7%	-21.4%	+0.8%	-10.3%	+4.4%	-14.4%	+9.7%	-10.9%	+11.6%	-14.8%	+10.0%	-1.2%	-2.7%	-17.6%	+10.7%	+0.2%	-0.2%	-10.8%
YoY Change	—	—	—	—	-14.8%	-24.2%	-25.8%	-19.3%	-12.1%	-12.7%	-6.6%	-7.0%	-6.8%	+3.3%	-9.9%	-12.9%	-12.3%	-11.1%	-8.8%	-1.3%

Range$273.50M – $539.20M

CAGR-12.0%

Avg YoY Growth-11.4%

Median YoY Growth-11.6%

Current Streak2 quarters decline

Similar Metrics at Other Companies

United TherapeuticsUTHR View metric

IQVIAIQV View metric

Johnson Controls InternationalJCI View metric

InsmedINSM View metric

Veeva SystemsVEEV View metric

ZoetisZTS View metric

Frequently Asked Questions

What is Viatris's japan, australia and new zealand segment — net sales?: Viatris (VTRS) reported japan, australia and new zealand segment — net sales of $273.50M in Q1 2026.
How has Viatris's japan, australia and new zealand segment — net sales changed year-over-year?: Viatris's japan, australia and new zealand segment — net sales decreased by 1.3% year-over-year, from $277.10M to $273.50M.
What is the long-term trend for Viatris's japan, australia and new zealand segment — net sales?: Over 4 years (2021 to 2025), Viatris's japan, australia and new zealand segment — net sales has grown at a -12.3% compound annual growth rate (CAGR), from $2.03B to $1.20B.
What does japan, australia and new zealand segment — net sales mean?: Total revenue earned from pharmaceutical sales in the Japan, Australia, and New Zealand region.